Thermo Fisher Molecular Diagnostics: Overview Of Technologies And Applications In Clinical Testing
Thermo Fisher Molecular Diagnostics: Instrumentation and Assay Types
Instrument categories and assay chemistries introduced earlier may be grouped by intended use and throughput. Real-time PCR instruments are often used for targeted detection and quantitation; in U.S. clinical practice they may support same-day reporting for many infectious disease assays. NGS platforms are typically applied when multiplexed variant detection or broader genomic profiling is required; U.S. clinical laboratories may choose benchtop sequencers for focused panels or larger instruments for higher throughput. Assay chemistries such as hydrolysis probes, amplicon-based NGS panels, or hybrid-capture methods each have trade-offs in sensitivity, input requirements, and hands-on time.
Choosing among assay types often involves considering per-sample cost drivers. For single-target PCR testing, reagent and consumable costs per sample may be relatively low, and instrument amortization can be favorable for moderate volumes. For NGS, costs per sample can decrease with higher batching and multiplexing but typically require more bioinformatics and data storage investment. U.S. laboratories often model expected test volumes, anticipated reimbursement environment, and staffing levels to estimate total cost of ownership for different platforms.
Manufacturers also supply assay kits and validated panels intended to simplify implementation; in the United States many clinical labs use these kits as part of an overall validated workflow. Even when using manufacturer-validated assays, U.S. CLIA regulations generally require laboratories to perform a verification study demonstrating performance in the local environment. Verification may include assessing limits of detection, precision, analytic specificity, and accuracy using reference materials or characterized clinical specimens.
Operational considerations include instrument maintenance, service agreements, and supply chain reliability. In the U.S., laboratories often maintain inventory levels of critical reagents and consider service contracts that include preventive maintenance and technical support. Planned instrument downtime and contingency plans for high-demand periods may factor into platform selection, especially for assays that support acute clinical decisions.